279 related articles for article (PubMed ID: 29223478)
1. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline
O'Reilly EM; Lee JW; Zalupski M; Capanu M; Park J; Golan T; Tahover E; Lowery MA; Chou JF; Sahai V; Brenner R; Kindler HL; Yu KH; Zervoudakis A; Vemuri S; Stadler ZK; Do RKG; Dhani N; Chen AP; Kelsen DP
J Clin Oncol; 2020 May; 38(13):1378-1388. PubMed ID: 31976786
[TBL] [Abstract][Full Text] [Related]
4. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
[TBL] [Abstract][Full Text] [Related]
5. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S
Ann Oncol; 2018 Jan; 29(1):154-161. PubMed ID: 29045554
[TBL] [Abstract][Full Text] [Related]
6. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategies in BRCA-positive pancreatic cancer.
Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
Chiorean EG; Guthrie KA; Philip PA; Swisher EM; Jalikis F; Pishvaian MJ; Berlin J; Noel MS; Suga JM; Garrido-Laguna I; Cardin DB; Radke MR; Duong M; Bellasea S; Lowy AM; Hochster HS
Clin Cancer Res; 2021 Dec; 27(23):6314-6322. PubMed ID: 34580114
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
[No Abstract] [Full Text] [Related]
11. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.
Diéras V; Han HS; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Loirat D; Ratajczak C; Adamu H; Girardi V; Arun BK
Eur J Cancer; 2024 Mar; 200():113580. PubMed ID: 38309017
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract][Full Text] [Related]
14. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
Reiss KA; Herman JM; Armstrong D; Zahurak M; Fyles A; Brade A; Milosevic M; Dawson LA; Scardina A; Fischer P; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Stayner LA; Siu LL; Azad NS
Gynecol Oncol; 2017 Mar; 144(3):486-490. PubMed ID: 28109627
[TBL] [Abstract][Full Text] [Related]
15. The role of PARP inhibitors in
Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
[TBL] [Abstract][Full Text] [Related]
16. Whole genomes redefine the mutational landscape of pancreatic cancer.
Waddell N; Pajic M; Patch AM; Chang DK; Kassahn KS; Bailey P; Johns AL; Miller D; Nones K; Quek K; Quinn MC; Robertson AJ; Fadlullah MZ; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Wilson PJ; Markham E; Cloonan N; Anderson MJ; Fink JL; Holmes O; Kazakoff SH; Leonard C; Newell F; Poudel B; Song S; Taylor D; Waddell N; Wood S; Xu Q; Wu J; Pinese M; Cowley MJ; Lee HC; Jones MD; Nagrial AM; Humphris J; Chantrill LA; Chin V; Steinmann AM; Mawson A; Humphrey ES; Colvin EK; Chou A; Scarlett CJ; Pinho AV; Giry-Laterriere M; Rooman I; Samra JS; Kench JG; Pettitt JA; Merrett ND; Toon C; Epari K; Nguyen NQ; Barbour A; Zeps N; Jamieson NB; Graham JS; Niclou SP; Bjerkvig R; Grützmann R; Aust D; Hruban RH; Maitra A; Iacobuzio-Donahue CA; Wolfgang CL; Morgan RA; Lawlor RT; Corbo V; Bassi C; Falconi M; Zamboni G; Tortora G; Tempero MA; ; Gill AJ; Eshleman JR; Pilarsky C; Scarpa A; Musgrove EA; Pearson JV; Biankin AV; Grimmond SM
Nature; 2015 Feb; 518(7540):495-501. PubMed ID: 25719666
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
[TBL] [Abstract][Full Text] [Related]
18. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
Cecchini M; Walther Z; Wei W; Hafez N; Pilat MJ; Boerner SA; Durecki DE; Eder JP; Schalper KA; Chen AP; LoRusso P
Cancer Res Commun; 2023 Jun; 3(6):1113-1117. PubMed ID: 37377610
[TBL] [Abstract][Full Text] [Related]
19. Importance of
Martínez-Galán J; Rodriguez I; Caba O
World J Gastroenterol; 2021 Oct; 27(39):6515-6521. PubMed ID: 34754149
[TBL] [Abstract][Full Text] [Related]
20. PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.
Yuan H; Xiu L; Li N; Li Y; Wu L; Yao H
J Gynecol Oncol; 2024 Jan; ():. PubMed ID: 38246184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]